Event-Driven Stocks

Y-mAbs Therapeutics, Inc.

YMAB

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 3 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue$87.7M$84.8M$65.3M$34.9M$20.8M$0
Operating income−$31.2M−$25.7M−$94.8M−$115.4M−$119.9M−$83.0M
Net income−$29.7M−$21.4M−$95.6M−$55.3M−$119.3M−$81.0M
Total assets$119.9M$127.9M$141.5M$212.8M$132.0M$216.4M
Total liabilities$27.9M$26.9M$32.2M$32.7M$26.2M$17.5M
Equity$92.0M$101.0M$109.2M$180.1M$105.8M$198.9M
EPS (diluted)$-0.67$-0.49$-2.19$-1.28$-2.97$-2.30
Shares out.43.8M43.7M43.7M43.5M39.8M34.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
−35.6%
Net margin
−33.8%
Return on equity
−32.2%
Return on assets
−24.7%
Return on capital (ROCE)
−32.4%
Liabilities / assets
23.3%
Debt / equity
0.30×
Book value / share
$2.10
Revenue growth (YoY)
3.4%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
-7.44distress
Accruals / assets
−11.6%clean
Beneish M-Score
-3.04normal
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
55
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 3 warning● 3 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Sep 15, 20251.1M1.7-42.4%
Aug 29, 20251.9M1.7+11.3%
Aug 15, 20251.7M1.0-25.5%
Jul 31, 20252.2M11.9-10.4%
Jul 15, 20252.5M19.9-3.5%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)